Special Issue

Fungal Pathogens: Resistance and Novel Therapeutics

Message from the Guest Editors

Fungal infections play a surprising yet unrecognised health burden on the global population, with diseases ranging from superficial infections to life-threatening bloodstream infections. Most pathogenic fungi are regarded as opportunistic, capable of causing debilitating disease in immunocompromised individuals and are commonly associated with unacceptability high mortality rates, accounting for ~1.6 million deaths each year. In a climate where antimicrobial resistance continues to increase and the rate of new drug discovery slows, coupled with the unprecedented emergence of new fungal pathogens such as *Candida auris*, it is of paramount interest to fully understand the underlying mechanisms of resistance and use these findings to translate and identify alternative strategies for the management of fungal infections. This special issue welcomes original research and review articles and aims to collate the most recent findings on antifungal resistance and highlight potential novel therapeutics for the clinical management of these infections.

Guest Editors

Dr. Ryan Kean

Department of Biological and Biomedical Sciences, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK

Dr. Leighann Sherry

School of Life Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

Deadline for manuscript submissions

closed (30 June 2020)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/31970

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI